A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2017-11-08
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the efficacy and safety of oral enzalutamide
compared to bicalutamide in castrate men with metastatic prostate cancer who have progressed
while on Luteinizing Hormone Receptor Hormone (LHRH) agonist/antagonist or after receiving a
bilateral orchiectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborators:
Medivation LLC, a wholly owned subsidiary of Pfizer Inc. Medivation, Inc.